In contrast, circulating anti-Melan A CD4+ T cells producing IL-4 or IL-17 were associated with worse 5-year survival in metastatic melanoma patients, while anti-NY-ESO-1 CD4+ T cells (mainly TNF producers) did not have any impact [76]. This evidence concerns the gene CD4 and metastatic melanoma.